Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGIO Agios Pharmaceuticals

Trading 12-23 12:04:03 EST

35.08

-0.34

-0.96%

High35.60	Low34.60	Vol241.69K
Open35.42	D1 Closing35.42	Amplitude2.84%
Mkt Cap2.00B	Tradable Cap1.77B	Total Shares57.03M
T/O8.45M	T/O Rate0.48%	Tradable Shares50.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals","latestPrice":35.08,"timestamp":1734973435982,"preClose":35.42,"halted":0,"volume":241693,"delay":0,"floatShares":50522137,"shares":57030195,"eps":11.798295,"marketStatus":"Trading","change":-0.34,"latestTime":"12-23 12:04:03 EST","open":35.42,"high":35.6,"low":34.595,"amount":8453090.620035,"amplitude":0.028374,"askPrice":35.16,"askSize":72,"bidPrice":34.98,"bidSize":200,"shortable":3,"etf":0,"ttmEps":11.798295,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":35.42,"preHourTrading":{"tag":"盘前","latestPrice":35.42,"preClose":35.42,"latestTime":"09:11 EST","volume":289,"amount":10368.979557999999,"timestamp":1734963110043},"postHourTrading":{"tag":"盘后","latestPrice":35.42,"preClose":35.42,"latestTime":"17:55 EST","volume":1659209,"amount":58769183.587,"timestamp":1734735304940},"volumeRatio":0.392148,"impliedVol":0.6761,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/AGIO","defaultTab":"news","newsList":[{"id":"2492188373","title":"Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188373?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:53","pubTimestamp":1734526418,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  said Wednesday that the European Commission has granted orphan medicinal product designation to mitapivat, its oral small-molecule PK activator, for treating sickle cell disease.The company said it plans to share results of its phase 3 study assessing the efficacy and safety of mitapivat in late 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO","BK4139","BK4156"],"gpt_icon":0},{"id":"2492902754","title":"European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492902754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492902754?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:04","pubTimestamp":1734523489,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NI1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490704918","title":"Here's Why Agios Stock Plummeted More Than 20% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2490704918","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490704918?lang=en_us&edition=fundamental","pubTime":"2024-12-10 23:46","pubTimestamp":1733845560,"startTime":"0","endTime":"0","summary":"Shares of Agios Pharmaceuticals AGIO lost 21% yesterday after management revealed that two thalassemia patients who received its sole-marketed drug Pyrukynd  across two late-stage studies reported hepatocellular  injury in the first six months of treatment.This information was disclosed by Agios as part of an oral presentation at the ASH 2024 annual meeting when it presented detailed results from two phase III studies, ENERGIZE-T and ENERGIZE. While the ENERGIZE-T study evaluated Pyrukynd in adult participants with transfusion-dependent  alpha or beta-thalassemia, the ENERGIZE study evaluated the drug in non-transfusion-dependent  thalassemia patients.Alongside the oral presentation, Agios also disclosed that it has submitted regulatory filings in the United States, European Union, Kingdom of Saudi Arabia and United Arab Emirates seeking label expansion for Pyrukynd in both NTD and TD thalassemia patients.The above submissions also identify hepatocellular injury as a potential risk in ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-agios-stock-plummeted-154600986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4139","BK4585","BK4007","BK4196","BK4207","BK4566","CTMX","RPRX","TD","AGIO"],"gpt_icon":0},{"id":"2490867014","title":"Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2490867014","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490867014?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:39","pubTimestamp":1733841571,"startTime":"0","endTime":"0","summary":"Scotiabank raised the firm’s price target on Agios Pharmaceuticals  to $75 from $53 and keeps an Outperform rating on the shares. The firm increased its price target on the stock given the promising results presented for its phase 3 ENERGIZE-T study as well as its announcement it filed for the regulatory approval of mitapivat for the treatment of thalassemia in four regions, the analyst tells investors.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Agios presents results from Phase 3 ENERGIZE-T Study of Mitapivat. Agios Pharmaceuticals to present new data on mitapivat, tebapivat. Agios Pharmaceuticals reports Q3 EPS $16.22, consensus $1.11","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/agios-pharmaceuticals-price-target-raised-143931999.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-price-target-raised-143931999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO"],"gpt_icon":0},{"id":"2490094230","title":"RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094230","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094230?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:12","pubTimestamp":1733832775,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) has an average rating of overweight and mean price target of $56.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO"],"gpt_icon":0},{"id":"2490099657","title":"Agios Pharma (AGIO) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2490099657","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490099657?lang=en_us&edition=fundamental","pubTime":"2024-12-10 19:28","pubTimestamp":1733830089,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agios-pharma-agio-receives-a-buy-from-rbc-capital-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agios-pharma-agio-receives-a-buy-from-rbc-capital-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BK4207","BK4139"],"gpt_icon":0},{"id":"2490908321","title":"Small U.S. Stocks Decrease; Agios Pharmaceuticals Posts Biggest Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2490908321","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490908321?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:20","pubTimestamp":1733779200,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies dropped Monday, as the Russell 2000 Index declined 0.7%, and the S&P Small Cap 600 Index was down 0.2%.Among companies with a market value of $1 billion to $6.7 billion, Agios Pharmaceuticals Inc. was the biggest laggard during the session, dropping 21%, followed by shares of Riot Platforms Inc., which dropped 13%. Shares of Zeta Global Holdings Corp. dropped 12%, Petco Health & Wellness Co. Inc. shares plunged 11%, and Applied Digital Corp. plunged 11%.Pactiv Evergreen Inc. was the best performer, surging 18%, followed by BlackBerry Ltd., which surged 14%. SSR Mining Inc. shares surged 12%, Plug Power Inc. jumped 12%, and shares of Asana Inc. Cl A jumped 12%.Major U.S. stock indexes decreased Monday with the Nasdaq Composite Index dropping 0.6%. Meanwhile, the S&P 500 Index dropped 0.6%, and the Dow Jones Industrial Average dropped 0.5%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2490705837","title":"Agios Pharmaceuticals Down Nearly 22%, on Pace for Record Percent Decrease -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2490705837","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490705837?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:46","pubTimestamp":1733766360,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.  is currently at $48.09, down $13.55 or 21.98%. --Would be lowest close since Nov. 5, 2024, when it closed at $46.70. --Up 115.94% year-to-date; on pace for best year since 2014, when it rose 367.81%. --Down 64.38% from its all-time closing high of $135.01 on Jan. 14, 2015. --Up 119.29% from 52 weeks ago , when it closed at $21.93. --Traded as low as $48.04; lowest intraday level since Nov. 6, 2024, when it hit $47.80. --Down 22.06% at today's intraday low; largest intraday percent decrease since Dec. 7, 2015, when it fell as much as 22.44%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490704799","title":"Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490704799","media":"Blockhead","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490704799?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:02","pubTimestamp":1733763753,"startTime":"0","endTime":"0","summary":"Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2024/12/Stock-AgiosPharmaceuticals-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/12/Stock-AgiosPharmaceuticals-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/agios-pharmaceuticals-stock-thalassemia-treatment-mitapivat/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490024771","title":"Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2490024771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490024771?lang=en_us&edition=fundamental","pubTime":"2024-12-09 23:49","pubTimestamp":1733759340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2024 10:49 ET (15:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"2490202207","title":"Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2490202207","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490202207?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:04","pubTimestamp":1733753090,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund  and the iShares Biotechnology ETF  up 0.1%.Arcellx  shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.Agios Pharmaceuticals  shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.Beam Therapeutics  said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ACLX","BK4581","IBB","BEAM","BK4535","BK4588","XLV","BK4505","BK4585","AGIO","BK4556"],"gpt_icon":0},{"id":"2490749142","title":"Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2490749142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490749142?lang=en_us&edition=fundamental","pubTime":"2024-12-09 17:38","pubTimestamp":1733737091,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said.The company also said the study met all the key secondary endpoints, with mitapivat demonstrating a \"statistically significant\" reduction in additional measures of transfusion response compared with placebo.Based on results from two phase 3 studies, the drug developer said it plans to submit regulatory applications for mitapivat to treat transfusion-dependent and non-transfusion-dependent thalassemia patients in the US, EU, Saudi Arabia and the UAE.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490574507","title":"Agios presents results from Phase 3 ENERGIZE-T Study of Mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2490574507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490574507?lang=en_us&edition=fundamental","pubTime":"2024-12-09 05:35","pubTimestamp":1733693704,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK activ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-presents-results-from-phase-3-energize-t-study-of-mitapivat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-presents-results-from-phase-3-energize-t-study-of-mitapivat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490753275","title":"BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2490753275","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490753275?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:42","pubTimestamp":1733679763,"startTime":"0","endTime":"0","summary":"BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of MitapivatAt Ash 2024 And Provides Regulatory Update On MitapivatDec 8 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:AGIOS PRESENTS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUA7S5CHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490530357","title":"Agios Pharmaceuticals - Filed Regulatory Applications for Mitapivat US, EU, Saudi Arabia ,UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=2490530357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490530357?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:40","pubTimestamp":1733679600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUA7S5CHD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490275345","title":"Agios Presents Positive Results From Phase 3 Energize-T Study of Mitapivat at Ash 2024 and Provides Regulatory Update on Mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2490275345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490275345?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:40","pubTimestamp":1733679600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUA7S5CHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2490875327","title":"Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2490875327","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490875327?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:40","pubTimestamp":1733679600,"startTime":"0","endTime":"0","summary":"– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –。– ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia–。– Company Filed for Regulatory Approval of Mitapivat  for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates –。– Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted in San Diego onMonday, December 9at 7:00 a.m. PT –。“Treatment options for patients with transfusion-dependent thalassemia are extremely limited, and transfusions carry serious risks, such as iron overload, infections and immune reactions. There is a significant need for alternative treatments to manage this debilitating disease,” saidMaria Domenica Cappellini,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1.n_derrhoYaVfgBcvtg0w--~B/aD0xMzQxO3c9NzUwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c805cec60d1b895ac7995fe9db60d850","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1.n_derrhoYaVfgBcvtg0w--~B/aD0xMzQxO3c9NzUwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c805cec60d1b895ac7995fe9db60d850"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-presents-positive-results-phase-174000609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","AGIO","LU2065731478.USD","LU2463526074.USD","IE00BLDYK493.USD","BK4139","IE00B64QTZ34.USD","PK","BK4181","BK4218","BK4161","ASH","RBC"],"gpt_icon":0},{"id":"2489725163","title":"Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489725163","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489725163?lang=en_us&edition=fundamental","pubTime":"2024-12-07 00:31","pubTimestamp":1733502676,"startTime":"0","endTime":"0","summary":"A month has gone by since the last earnings report for Denali Therapeutics Inc. . Shares have lost about 21.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Denali Therapeutics due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging. Denali incurred a third-quarter 2024 loss of 63 cents per share, wider than the Zacks Consensus Estimate of a loss of 60 cents. The company reported a loss of 72 cents in the year-ago quarter.The bottom line improved year over year despite a rise in operating expenses, mainly due to an increase in the number of shares outstanding.In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations. Denali did not generate c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-denali-therapeutics-dnli-down-163116909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO","DNLI","SNY"],"gpt_icon":0},{"id":"2489446546","title":"Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489446546","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489446546?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:42","pubTimestamp":1733406120,"startTime":"0","endTime":"0","summary":"Investors in Agios Pharmaceuticals, Inc. AGIO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $17.50 Put had some of the highest implied volatility of all equity options today.Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.Clearly, options traders are pricing in a big move for Agios shares, but what is the fundamental picture for the company?To read this article on Zacks.com click here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/options-traders-betting-big-move-134200946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2489328684","title":"Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios","url":"https://stock-news.laohu8.com/highlight/detail?id=2489328684","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489328684?lang=en_us&edition=fundamental","pubTime":"2024-12-05 18:00","pubTimestamp":1733392800,"startTime":"0","endTime":"0","summary":"Chicago, IL – December 5, 2024 – Today, Zacks Equity Research discusses ResMed RMD, Haemonetics HAE, Phibro Animal Health PAHC and Agios Pharmaceuticals AGIO.The Zacks Medical - Products industry’s revenues are expected to continue to grow due to robust demand for surgeries and procedures, the launch of new products and expansion into new markets. An earlier-than-expected demand for respiratory products is also boosting sales. Industry players are raising the prices of their products and services to cope with the higher costs, thereby benefiting the top and bottom lines.Industry participants like ResMed, Haemonetics, Phibro Animal Health and Agios Pharmaceuticals have adapted to changing consumer preferences, and the majority of them are witnessing a rise in share price. These companies also carry a favorable Zacks Rank.AI, Medical Mechatronics & Robotics: The rising adoption of minimally-invasive robot-assisted surgeries, self-automated home-based care, use of IT in facilitating quick","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-industry-outlook-highlights-resmed-100000680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4548","LU0205194284.USD","BK4504","BK4181","LU0106261612.USD","LU0205193047.USD","BK4207","HAE","IE00BLDYK493.USD","BK4566","IE00B64QTZ34.USD","LU2008162690.USD","PAHC","RMD.AU","BK4218","BK4007","BK4139","PK","BK4198","LU1169589451.USD","SCD","LU0012050646.USD","TD","RMD","BK4567","AGIO","BK4585","BK4082","LU1169590202.USD","LU2177674079.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":-0.091},{"period":"1month","weight":-0.3515},{"period":"3month","weight":-0.2391},{"period":"6month","weight":-0.2167},{"period":"1year","weight":0.5488},{"period":"ytd","weight":0.5905}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.818182,"avgChangeRate":0.042769},{"month":2,"riseRate":0.636364,"avgChangeRate":0.059258},{"month":3,"riseRate":0.545455,"avgChangeRate":0.003251},{"month":4,"riseRate":0.545455,"avgChangeRate":0.006144},{"month":5,"riseRate":0.545455,"avgChangeRate":0.049654},{"month":6,"riseRate":0.636364,"avgChangeRate":0.046688},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.024214},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046002},{"month":9,"riseRate":0.5,"avgChangeRate":0.041136},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.014099},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063175},{"month":12,"riseRate":0.416667,"avgChangeRate":-0.046395}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agios Pharmaceuticals,AGIO,Agios Pharmaceuticals股票,Agios Pharmaceuticals股票老虎,Agios Pharmaceuticals股票老虎国际,Agios Pharmaceuticals行情,Agios Pharmaceuticals股票行情,Agios Pharmaceuticals股价,Agios Pharmaceuticals股市,Agios Pharmaceuticals股票价格,Agios Pharmaceuticals股票交易,Agios Pharmaceuticals股票购买,Agios Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction